Paclitaxel based vs oxaliplatin based regimens for advanced gastric cancer

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 8

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

331

HTML

3075

Figures (1-1)

213

Tables (1-1)

189

Sum=3808

Feb 28, 2011 (publication date) through Nov 5, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Article

World J Gastroenterol. Feb 28, 2011; 17(8): 1082-1087
Published online Feb 28, 2011. doi: 10.3748/wjg.v17.i8.1082

Table 1 Baseline characteristics of patients enrolled in this study (n = 73)

Characteristics	Patients (%)		P
	PCF(n = 50)	FOLFOX-4(n = 44)
Gender
Female	18	13	0.520
Male	32	31
Age (yr)
Median	59	58	0.876
Range	20-74	20-75
Histologic type
Adenocarcinoma	34	36	0.158
Adenosquamous carcinoma	3	1
Signet ring cell carcinoma	5	3
Mucinous carcinoma	7	3
Neuroendocrine carcinoma	1	1
No. of metastatic lesion
0-1	24	21	1
≥ 2	26	23
Stage
IIIb	22	17	0.677
IV	28	27
Prior adjuvant chemotherapy
No	38	31	0.642
Yes	12	13

PCF: Paclitaxel combined with fluorouracil plus cisplatin; FOLFOX-4: Oxaliplatin combined with fluorouracil plus leucovorin.

Citation: Li XD, Shen H, Jiang JT, Zhang HZ, Zheng X, Shu YQ, Wu CP. Paclitaxel based vs oxaliplatin based regimens for advanced gastric cancer. World J Gastroenterol 2011; 17(8): 1082-1087
URL: https://www.wjgnet.com/1007-9327/full/v17/i8/1082.htm
DOI: https://dx.doi.org/10.3748/wjg.v17.i8.1082